February 23, 2021
3 min read
Disclosures: The study was funded by Janssen Pharmaceuticals, the sponsor of the REVEAL Registry. Benza reports he received grants from the American Heart Association, Bayer, the National Heart, Lung, and Blood Institute, and United Therapeutics; and received research support and served as a paid consultant for Janssen Please see the study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
Back to Healio
Use of an abridged version of the REVEAL 2.0 risk calculator, REVEAL Lite 2, provided a simplified method of mortality risk assessment for patients with pulmonary arterial hypertension, researchers reported in Chest.
“REVEAL Lite 2 was developed to provide clinicians with a simplified risk calculation method that can be routinely implemented in clinical practice, where data for patients may lack and be time-constrained,” Raymond L…